109 related articles for article (PubMed ID: 7630170)
1. Immunohistochemically demonstrated expression of HLA-DR antigen in colorectal adenocarcinomas and its relation to clinicopathological features.
Morita M; Tanaka K; Kawanishi H; Tsuji M; Ookusa T; Takada H; Okamura A; Hioki K
J Surg Oncol; 1995 Aug; 59(4):233-8. PubMed ID: 7630170
[TBL] [Abstract][Full Text] [Related]
2. Low intercellular adhesion molecule 1 and high 5T4 expression on tumor cells correlate with reduced disease-free survival in colorectal carcinoma patients.
Mulder WM; Stern PL; Stukart MJ; de Windt E; Butzelaar RM; Meijer S; Adér HJ; Claessen AM; Vermorken JB; Meijer CJ; Wagstaff J; Scheper RJ; Bloemena E
Clin Cancer Res; 1997 Nov; 3(11):1923-30. PubMed ID: 9815581
[TBL] [Abstract][Full Text] [Related]
3. HLA-DR antigen expression in colorectal carcinomas: influence of expression by IFN-gamma in situ and its association with tumour progression.
Matsushita K; Takenouchi T; Kobayashi S; Hayashi H; Okuyama K; Ochiai T; Mikata A; Isono K
Br J Cancer; 1996 Mar; 73(5):644-8. PubMed ID: 8605101
[TBL] [Abstract][Full Text] [Related]
4. Combined expression of HLA-DR antigen and proliferating cell nuclear antigen correlate with colorectal cancer prognosis.
Kunihiro M; Tanaka S; Haruma K; Yoshihara M; Sumii K; Kajiyama G; Shimamoto F
Oncology; 1998; 55(4):326-33. PubMed ID: 9663422
[TBL] [Abstract][Full Text] [Related]
5. HLA-DR expression is associated with better prognosis in sporadic Australian clinicopathological Stage C colorectal cancers.
Walsh MD; Dent OF; Young JP; Wright CM; Barker MA; Leggett BA; Bokey L; Chapuis PH; Jass JR; Macdonald GA
Int J Cancer; 2009 Sep; 125(5):1231-7. PubMed ID: 19462453
[TBL] [Abstract][Full Text] [Related]
6. Characterising the prognostic potential of HLA-DR during colorectal cancer development.
Dunne MR; Phelan JJ; Michielsen AJ; Maguire AA; Dunne C; Martin P; Noonan S; Tosetto M; Geraghty R; Fennelly D; Sheahan K; Ryan EJ; O'Sullivan J
Cancer Immunol Immunother; 2020 Aug; 69(8):1577-1588. PubMed ID: 32306077
[TBL] [Abstract][Full Text] [Related]
7. How many lymph nodes should be examined in Dukes' B colorectal cancer? Determination on the basis of cumulative survival rate.
Yoshimatsu K; Ishibashi K; Umehara A; Yokomizo H; Yoshida K; Fujimoto T; Watanabe K; Ogawa K
Hepatogastroenterology; 2005; 52(66):1703-6. PubMed ID: 16334761
[TBL] [Abstract][Full Text] [Related]
8. Strong HLA-DR antigen expression on cancer cells relates to better prognosis of colorectal cancer patients: Possible involvement of c-myc suppression by interferon-gamma in situ.
Matsushita K; Takenouchi T; Shimada H; Tomonaga T; Hayashi H; Shioya A; Komatsu A; Matsubara H; Ochiai T
Cancer Sci; 2006 Jan; 97(1):57-63. PubMed ID: 16367922
[TBL] [Abstract][Full Text] [Related]
9. Low levels of insulin-like growth factor type 1 receptor expression at cancer cell membrane predict liver metastasis in Dukes' C human colorectal cancers.
Nakamura M; Miyamoto S; Maeda H; Zhang SC; Sangai T; Ishii G; Hasebe T; Endoh Y; Saito N; Asaka M; Ochiai A
Clin Cancer Res; 2004 Dec; 10(24):8434-41. PubMed ID: 15623623
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of microRNA-21 as a biomarker in each Dukes' stage of colorectal cancer.
Fukushima Y; Iinuma H; Tsukamoto M; Matsuda K; Hashiguchi Y
Oncol Rep; 2015 Feb; 33(2):573-82. PubMed ID: 25421755
[TBL] [Abstract][Full Text] [Related]
11. Expression of HLA-DR antigen in large bowel carcinoma.
Chang ES; Sohn SS
J Korean Med Sci; 1995 Oct; 10(5):334-41. PubMed ID: 8750059
[TBL] [Abstract][Full Text] [Related]
12. Heat shock protein 70 and HLA-DR molecules tissue expression. Prognostic implications in colorectal cancer.
Lazaris AC; Theodoropoulos GE; Davaris PS; Panoussopoulos D; Nakopoulou L; Kittas C; Golematis BC
Dis Colon Rectum; 1995 Jul; 38(7):739-45. PubMed ID: 7607036
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical expression of bcl-2 in Dukes' stage B and C colorectal carcinoma patients: correlation with p53 and ki-67 in evaluating prognostic significance.
Zavrides H; Zizi-Sermpetzoglou A; Elemenoglou I; Papatheofanis I; Peros G; Athanasas G; Panousopoulos D
Pol J Pathol; 2005; 56(4):179-85. PubMed ID: 16477877
[TBL] [Abstract][Full Text] [Related]
14. Venous invasion and down-regulation of p21(WAF1/CIP1) are associated with metastasis in colorectal carcinomas.
Mitomi H; Mori A; Kanazawa H; Nishiyama Y; Ihara A; Otani Y; Sada M; Kobayashi K; Igarashi M
Hepatogastroenterology; 2005; 52(65):1421-6. PubMed ID: 16201087
[TBL] [Abstract][Full Text] [Related]
15. Local immune response to tumor invasion in esophageal squamous cell carcinoma. The expression of human leukocyte antigen-DR and lymphocyte infiltration.
Sadanaga N; Kuwano H; Watanabe M; Maekawa S; Mori M; Sugimachi K
Cancer; 1994 Jul; 74(2):586-91. PubMed ID: 8033037
[TBL] [Abstract][Full Text] [Related]
16. Influence of major histocompatibility complex class I and II antigens on survival in colorectal carcinoma.
Möller P; Momburg F; Koretz K; Moldenhauer G; Herfarth C; Otto HF; Hämmerling GJ; Schlag P
Cancer Res; 1991 Jan; 51(2):729-36. PubMed ID: 1985791
[TBL] [Abstract][Full Text] [Related]
17. The value of immunohistochemistry for collagen IV expression in colorectal carcinomas.
Offerhaus GJ; Giardiello FM; Bruijn JA; Stijnen T; Molyvas EN; Fleuren GJ
Cancer; 1991 Jan; 67(1):99-105. PubMed ID: 1985727
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological features of serrated adenocarcinoma defined by Mäkinen in dukes' B colorectal carcinoma.
Shida Y; Fujimori T; Tanaka H; Fujimori Y; Kimura R; Ueda H; Ichikawa K; Tomita S; Nagata H; Kubota K; Tsubaki M; Kato H; Yao T; Sugai T; Sugihara K; Ohkura Y; Imura J
Pathobiology; 2012; 79(4):169-74. PubMed ID: 22433973
[TBL] [Abstract][Full Text] [Related]
19. Strong HLA-DR expression in large bowel carcinomas is associated with good prognosis.
Andersen SN; Rognum TO; Lund E; Meling GI; Hauge S
Br J Cancer; 1993 Jul; 68(1):80-5. PubMed ID: 8318425
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous detection of apoptosis and proliferation in colorectal carcinoma by multiparameter flow cytometry allows separation of high and low-turnover tumors with distinct clinical outcome.
Rupa JD; de Bruïne AP; Gerbers AJ; Leers MP; Nap M; Kessels AG; Schutte B; Arends JW
Cancer; 2003 May; 97(10):2404-11. PubMed ID: 12733138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
